There are currently 2781 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy
NCT05531565
Recruiting
The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity measured by the Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) score [Parts A and B (US)] and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score [Part B (ROW)] in participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Register for Updates
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239
Recruiting
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Breast Cancer
Register for Updates
Multi-center Evaluation of the Clinical Utility of ESD in the Western Population
NCT02989818
Recruiting
The aim of this multi-center study is to prospectively document the clinical utility of ESD.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Endoscopic Submucosal Dissection
Register for Updates
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04428788
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Prostatic Neoplasms
Register for Updates
American Lung Association (ALA) Lung Health Cohort
NCT04543461
Recruiting
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Gender:
All
Ages:
Between 25 years and 35 years
Trial Updated:
06/14/2024
Locations: Brigham and Women's, Boston, Massachusetts
Conditions: Lung Diseases
Register for Updates
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
NCT04921787
Recruiting
This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.
Gender:
All
Ages:
All
Trial Updated:
06/14/2024
Locations: Boston University, Boston, Massachusetts
Conditions: Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Register for Updates
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
NCT04450693
Recruiting
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Boston Medical Center, Boston, Massachusetts +1 locations
Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Register for Updates
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667
Recruiting
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as pla... Read More
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
06/14/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437
Recruiting
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During thi... Read More
Gender:
All
Ages:
1 month and above
Trial Updated:
06/14/2024
Locations: Tufts / Neely Cancer Center, Boston, Massachusetts +1 locations
Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Register for Updates
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
NCT03107780
Recruiting
This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Glioblastoma, Gliosarcoma, Recurrent Glioblastoma, MGMT-Unmethylated Glioblastoma
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
All
Ages:
Between 0 years and 25 years
Trial Updated:
06/14/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Severe Aplastic Anemia
Register for Updates
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
NCT03301506
Recruiting
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Primary Biliary Cirrhosis
Register for Updates